Header Image
News Room / Announcing "The End of Opiates" Fundraiser to Benefit Dr. Daniele Piomelli's Lab at UC Irvine on August 26th in Costa Mesa; Hosted by Cultivation Technologies, Inc. and Abecis Pharma

Announcing "The End of Opiates" Fundraiser to Benefit Dr. Daniele Piomelli's Lab at UC Irvine on August 26th in Costa Mesa; Hosted by Cultivation Technologies, Inc. and Abecis Pharma

IRVINE, CA / ACCESSWIRE / August 16, 2016 / Cultivation Technologies, Inc. a leader in the legal cannabis industry, announced today the details for a fundraiser to benefit cannabinoid research at Dr. Daniele Piomelli's laboratory at University of California, Irvine.

WHAT: "The End of Opiates," an educational event and fundraiser, was organized to raise research funds and awareness for Dr. Daniele Piomelli's lab at the Gillespie Neuroscience Research Facility; UC Irvine. Research conducted at the lab could directly impact the global epidemic surrounding the abuse of opiates and opioids through research of cannabinoid-based therapeutics. Networking opportunities abound - food and beverages will be provided to all attendees.

WHEN: August 26th, 2016 from 7PM to 10PM

WHERE: Avenue of the Arts Hotel, 3350 Avenue of the Arts, Costa Mesa, CA 92626

WHY: Millions of people in the United States alone are plagued by the opiate and opioid epidemic - thousands die annually as a direct result of prescription medication addiction or overdose. Physicians have few alternatives to treat severe or chronic pain. Research from Dr. Piomelli's lab seeks to change that.

WHO: Philanthropists, physicians, students, cannabis industry leaders and entrepreneurs, politicians, and medical or cannabis industry stakeholders should attend. Media is encouraged and press credentials will be honored in lieu of donations.

Tickets are available for a nominal $195 donation through Eventbrite: https://endofopiates.eventbrite.com

Justin Beck, CEO of Cultivation Technologies, Inc., stated "we are committed to advancing cannabinoid research, and appreciate Dr. Piomelli's objectivity and support of the CARERS Act. We have a moral obligation to act - his lab at UC Irvine and their focus on pain could revolutionize standards of care and save countless lives."

Companies which support cannabinoid research can sponsor the event. Packages start at $2,500. Donations of any level are encouraged, and all net proceeds benefit cannabinoid research at Dr. Piomelli's lab. Contact Michelle Guthrie (888) 851-9802 x114 or [email protected] for more details.

About Dr. Daniele Piomelli - Keynote Speaker & Panelist

Dr. Piomelli recently testified as an expert witness to a United States Senate committee about the CARERS Act, which would provide further protections to the legal cannabis industry and medical research. He is editor of "Cannabis & Cannabinoid Research," the only peer-reviewed scientific publication dedicated to cannabis. Recognized as a global leader in cannabinoid research, Daniele Piomelli was born and educated in Naples, Italy where he earned his degree of Doctor of Pharmacy in 1982. He studied pharmacology and neuroscience with James H. Schwartz and Eric Kandel at Columbia University, and later with Paul Greengard at the Rockefeller University. Both of his mentors received the Nobel Prize in 2000 for their contributions to medicine. After working at the INSERM in Paris, and at the Neurosciences Institute in San Diego, with Nobel Laureate Gerald Edelman, Dr. Piomelli joined the University of California, Irvine where he is now Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry. He is the founding director of the unit of drug discovery and development (D3) at the Italian Institute of Technology in Genoa, Italy. He is author to more than 400 peer-reviewed articles in journals such as Nature, Science, PNAS, and Nature Neuroscience, three full-length books, and 30 patents.

About Stephen Goldner - Keynote Speaker & Panelist

Stephen Goldner is a regulatory and FDA expert and founder of Abecis Pharma, a pharmaceutical company dedicated to the development of cannabis-based therapeutics for FDA approval. In 1972, Goldner co-invented both the liquid form of methadone as well urine screening while working as a forensic toxicologist . As founder of Regulatory Affairs Associates LLC, a consulting firm for companies seeking regulatory approval from the FDA, Goldner has helped get more than 240 drugs and devices approved and in doing so helped create over 200 companies with over 10,000 employees. Stephen Goldner serves as an FDA Advisor to NIH, advising medical device and drug developers and grant awardees. He spoke at TEDx Detroit 2014 and TEDMED 2015. Stephen Goldner serves FOCUS Foundation Of Cannabis Unified Standards as Chairman, USA Cannabis Laboratory Standards Setting Committee & Chairman, USA Cannabis Clinical Trials Standards Setting Committee.

About Cultivation Technologies, Inc. ("CTI")

Cultivation Technologies, Inc. is a provider of infrastructure and brands to the legal cannabis industry. The first major project (which is now fully entitled with a conditional use permit) for the company is in Coachella, California which will span 111,500 square feet including four cultivation centers, two manufacturing facilities, a testing lab, a distributor with transportation hub, and a pharmaceutical office for Abecis Pharma. The company expects to replicate this model in other municipalities in California and other legal markets. Cultivation Technologies supports cannabinoid research and the development of pharmaceuticals utilizing cannabis compounds; CTI is also in development stage of a molecular breeding program which utilizes modern genomic tools and high throughput screening to produce uniform hybrid cultivars with defined and reproducible chemical profiles which have been tailored for specific medical indications. Investors and media are encouraged to visit www.CultivationTech.com to learn more.

Tickets & Donations: https://endofopiates.eventbrite.com

Sponsors & Media: [email protected]

SOURCE: Cultivation Technologies, Inc.

Top